Carla is an accomplished scientist with over 15 years of experience in oncology. Her passion is
to translate cutting-edge research into novel and effective therapeutic strategies for cancer
patients. She is bringing her experience in tumor biology, drug discovery and scientific
innovation to initiate and advance pioneering R&D programs at BrYet.

Carla earned her M.S. in Biological Sciences from the University of Trieste and her Ph.D. in
Clinical Sciences and Technologies from the University of Udine. She held scientist roles at
leading institutions including Columbia University, Memorial Sloan Kettering Cancer Center, and
MD Anderson Cancer Center, where she made key discoveries about genetic and epigenetic
tumor drivers. In addition to her academic achievements, Carla has successfully translated her
expertise into the pharmaceutical industry. At Constellation Pharmaceuticals and Sanofi, she led multidisciplinary teams and applied her deep knowledge of cancer biology to identify new
therapeutic targets and advance drug development programs, with a focus on integrating AI
tools to accelerate discovery processes.

Carla’s achievements include the generation of a First-in-Class small molecule inhibitor for a
novel cancer target, a patent for specific tumor antibodies for immunodiagnosis and
immunotherapy applications, in-licensing of an early-stage therapeutic asset, and authoring 18
publications cited over 1,500 times. Carla is also recognized for her collaborative approach, and
ability to establish partnerships and maintain strategic relationships with external stakeholders.
Her work continues to bridge fundamental research and clinical applications, aiming to deliver
transformative therapies for patients in critical need.